PONIARD PHARMACEUTICALS, INC. - FORM 10-Q - XML - IDEA: XBRL DOCUMENT - October 28, 2011



Attached files
FileFilename
EXCEL - IDEA: XBRL DOCUMENT - PONIARD PHARMACEUTICALS, INC.Financial_Report.xls
10-Q - FORM 10-Q - PONIARD PHARMACEUTICALS, INC.d239788d10q.htm
XML - IDEA: XBRL DOCUMENT - PONIARD PHARMACEUTICALS, INC.R7.htm
XML - IDEA: XBRL DOCUMENT - PONIARD PHARMACEUTICALS, INC.R3.htm
XML - IDEA: XBRL DOCUMENT - PONIARD PHARMACEUTICALS, INC.R8.htm
XML - IDEA: XBRL DOCUMENT - PONIARD PHARMACEUTICALS, INC.R6.htm
XML - IDEA: XBRL DOCUMENT - PONIARD PHARMACEUTICALS, INC.R1.htm
XML - IDEA: XBRL DOCUMENT - PONIARD PHARMACEUTICALS, INC.R9.htm
XML - IDEA: XBRL DOCUMENT - PONIARD PHARMACEUTICALS, INC.R2.htm
XML - IDEA: XBRL DOCUMENT - PONIARD PHARMACEUTICALS, INC.R4.htm
XML - IDEA: XBRL DOCUMENT - PONIARD PHARMACEUTICALS, INC.R13.htm
XML - IDEA: XBRL DOCUMENT - PONIARD PHARMACEUTICALS, INC.R12.htm
XML - IDEA: XBRL DOCUMENT - PONIARD PHARMACEUTICALS, INC.R10.htm
XML - IDEA: XBRL DOCUMENT - PONIARD PHARMACEUTICALS, INC.R14.htm
XML - IDEA: XBRL DOCUMENT - PONIARD PHARMACEUTICALS, INC.R16.htm
XML - IDEA: XBRL DOCUMENT - PONIARD PHARMACEUTICALS, INC.R15.htm
XML - IDEA: XBRL DOCUMENT - PONIARD PHARMACEUTICALS, INC.R18.htm
XML - IDEA: XBRL DOCUMENT - PONIARD PHARMACEUTICALS, INC.R11.htm
EX-31.1 - SECTION 302 CEO CERTIFICATION - PONIARD PHARMACEUTICALS, INC.d239788dex311.htm
EX-32.2 - SECTION 906 CFO CERTIFICATION - PONIARD PHARMACEUTICALS, INC.d239788dex322.htm
EX-32.1 - SECTION 906 CEO CERTIFICATION - PONIARD PHARMACEUTICALS, INC.d239788dex321.htm
EX-31.2 - SECTION 302 CFO CERTIFICATION - PONIARD PHARMACEUTICALS, INC.d239788dex312.htm
XML - IDEA: XBRL DOCUMENT - PONIARD PHARMACEUTICALS, INC.R17.htm
v2.3.0.15
Condensed Consolidated Statements Of Cash Flows (USD $)
In Thousands
9 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Cash flows from operating activities:  
Net loss$ (10,875)$ (24,884)
Adjustments to reconcile net loss to net cash used in operating activities:  
Depreciation and amortization951989
Amortization of discount on note payable0820
Gain realized on sale of investment securities(8)0
Accretion of premium on investment securities14390
Loss on disposal of facilities and equipment058
Restructuring0321
Decrease in restricted cash for operating lease1360
Interest accrued on capital lease obligation6666
Share-based compensation issued for services(12)369
Share-based employee compensation2,5196,998
Change in operating assets and liabilities:  
Prepaid expenses and other assets483(25)
Accounts payable1,091730
Accrued liabilities224(5,062)
Net cash used in operating activities(5,411)(19,230)
Cash flows from investing activities:  
Proceeds from maturities of investment securities3,03222,089
Purchases of investment securities0(7,322)
Facilities and equipment purchases(9)(7)
Proceeds from disposals of equipment and facilities058
Net cash provided by investing activities3,02314,818
Cash flows from financing activities:  
Repayment of principal on note payable0(6,589)
Repayment of capital lease obligation0(38)
Decrease in restricted cash0123
Net proceeds from issuance of common stock3,1846,092
Payment of preferred dividends(96)(96)
Net cash provided by (used in) financing activities3,088(508)
Net increase (decrease) in cash and cash equivalents700(4,920)
Cash and cash equivalents:  
Beginning of period1,28415,938
End of period1,98411,018
Supplemental disclosure of non-cash financing activities:  
Accrual of preferred dividends144118
Preferred stock dividends, in-kind0570
Supplemental disclosure of cash paid during the period for:  
Interest$ 0$ 897

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA



This web site and associated pages are not associated with, endorsed by, or sponsored by PONIARD PHARMACEUTICALS, INC. and has no official or unofficial affiliation with PONIARD PHARMACEUTICALS, INC.


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.